Detalles de la búsqueda
1.
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
N Engl J Med
; 386(5): 437-448, 2022 02 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35045221
2.
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
N Engl J Med
; 385(20): 1856-1867, 2021 11 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34534429
3.
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 24(4): 392-402, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36878237
4.
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 24(12): 1334-1348, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38039991
5.
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
Br J Cancer
; 128(2): 255-265, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36482193
6.
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
Gynecol Oncol
; 178: 119-129, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37862791
7.
Outcomes associated with treatment to all sites of disease in patients with stage IVB cancer of the cervix.
Int J Gynecol Cancer
; 33(5): 683-691, 2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36963801
8.
A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.
Gynecol Oncol
; 167(2): 213-225, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36192237
9.
Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study.
Gynecol Oncol
; 166(2): 211-218, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35361487
10.
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.
Gynecol Oncol
; 161(2): 496-501, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33637348
11.
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Gynecol Oncol
; 163(3): 490-497, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34602290
12.
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Gynecol Oncol
; 161(3): 668-675, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33752918
13.
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Lancet Oncol
; 21(10): 1353-1365, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32919526
14.
Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response.
Mol Carcinog
; 59(7): 736-744, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32250515
15.
Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
Oncologist
; 24(5): 640-647, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30777894
16.
TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanoma.
Cancer Immunol Immunother
; 68(9): 1493-1500, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31501955
17.
Efficacy and safety of niraparib as maintenance treatment in older patients (≥â¯70â¯years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
Gynecol Oncol
; 152(3): 560-567, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30638768
18.
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.
Int J Gynecol Cancer
; 29(9): 1396-1404, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31685558
19.
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
Br J Cancer
; 119(9): 1075-1085, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30353045
20.
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
N Engl J Med
; 372(26): 2521-32, 2015 Jun 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-25891173